Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues through the use of its FLAIRE platform based on ...

Initial feasibility study of its soluble, Ph neutral, fast acting granular or powder drug delivery system is completeTest results support the next development step with Phase 1clinical trial expected ...

NexoBrid ® is a topically administered biological orphan drug that enzymatically removes eschar while preserving viable ...

The Company submitted an sNDA for ZORYVE foam for scalp and body psoriasis to the FDA based on the positive results from the pivotal ARRECTOR Phase 3 trial and a Phase 2b trial, which was accepted by ...

Federal tech workers stage mass resignation from Musk's DOGE, citing refusal to participate in dismantling government ...

Adial Pharmaceuticals (ADIL) announced a “positive” response from the U.S. FDA regarding its proposed in vitro bridging strategy for AD04. The ...

Contract drug manufacturer Thermo Fisher Scientific said on Tuesday it will buy Solventum's purification and filtration ...

Now is the time to begin reformulating foods and beverages with natural dyes if companies want to comply with upcoming state and federal bans of select synthetic colors and additives - though ...

Entrada Therapeutics can plough on with the development of its Duchenne muscular dystrophy (DMD) therapy, ENTR-601-44, now ...

The biggest technical challenge for adaptive deep brain stimulation (aDBS) is how small brain signals are, Medtronic's Scott ...